Resultats de la cerca - Henrik Hjorth‐Hansen

Refinar resultats
  1. 1
    Hepatocyte growth factor and its receptor c-met in multiple myeloma

    Hepatocyte growth factor and its receptor c-met in multiple myeloma per Magne Börset, Henrik Hjorth‐Hansen, Carina Seidel, Anders Sundan, Anders Waage

    Publicat 1996
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Interleukin-21 is a growth and survival factor for human myeloma cells

    Interleukin-21 is a growth and survival factor for human myeloma cells per Anne‐Tove Brenne, Torstein B. Rø, Anders Waage, Anders Sundan, Magne Börset, Henrik Hjorth‐Hansen

    Publicat 2002
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up per Andreas Hochhaus, Susanne Saußele, Gianantonio Rosti, F-X Mahon, J. Janssen, Henrik Hjorth‐Hansen, Johan Richter, Christian Buske

    Publicat 2017
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel

    Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel per Martin C. Müller, Francisco Cervantes, Henrik Hjorth‐Hansen, Jeroen J.W.M. Janssen, Dragana Milojković, Delphine Réa, Gianantonio Rosti

    Publicat 2017
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  5. 5
    IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome

    IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome per Niklas Landberg, Nils Hansen, Maria Askmyr, Helena Ågerstam, Carin Lassen, Marianne Rissler, Henrik Hjorth‐Hansen, Satu Mustjoki, Marcus Järås, Johan Richter, Thoas Fioretos

    Publicat 2015
    Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:
  6. 6
    High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease

    High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease per Sigbjørn Berentsen, Ulla Randen, Anne Marita Vågan, Henrik Hjorth‐Hansen, Anders Vik, Jakob Dalgaard, Eva‐Marie Jacobsen, A Thoresen, Klaus Beiske, Geir E. Tjønnfjord

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease

    Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease per Carina Seidel, Øyvind Hjertner, Niels Abildgaard, Lene Heickendorff, Martin Hjorth, Jan Westin, Johan Lanng Nielsen, Henrik Hjorth‐Hansen, Anders Waage, Anders Sundan, Magne Börset

    Publicat 2001
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

    The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses per Lisa Christiansson, Stina Söderlund, Sara M. Mangsbo, Henrik Hjorth‐Hansen, Martin Höglund, Berit Markevärn, Johan Richter, Leif Stenke, Satu Mustjoki, Angelica Loskog, Ulla Olsson‐Strömberg

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting

    CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting per Niklas Landberg, Sofia von Palffy, Maria Askmyr, Henrik Lilljebjörn, Carl Sandén, Marianne Rissler, Satu Mustjoki, Henrik Hjorth‐Hansen, Johan Richter, Helena Ågerstam, Marcus Järås, Thoas Fioretos

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

    Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML per Rebecca Warfvinge, Linda Geironson, Mikael N.E. Sommarin, Stefan Lang, Christine Karlsson, Teona Roschupkina, Leif Stenke, Jesper Stentoft, Ulla Olsson‐Strömberg, Henrik Hjorth‐Hansen, Satu Mustjoki, Shamit Soneji, Johan Richter, Göran Karlsson

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial

    Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial per Carlo Gambacorti‐Passerini, Tim H. Brümmendorf, Elisabetta Abruzzese, Kevin R. Kelly, Vivian G. Oehler, Valentín García‐Gutiérrez, Henrik Hjorth‐Hansen, Thomas Ernst, Eric Leip, Simon Purcell, Gérald Luscan, Andrea Viqueira, Francis J. Giles, Andreas Hochhaus

    Publicat 2024
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study (<scp>N</scp>ord<scp>CML</scp>006)

    Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study (<scp>N</scp>ord<... per Henrik Hjorth‐Hansen, Leif Stenke, Stina Söderlund, Arta Dreimane, Hans Ehrencrona, Tobias Gedde‐Dahl, Bjørn Tore Gjertsen, Martin Höglund, Perttu Koskenvesa, Kourosh Lotfi, Waleed Majeed, Berit Markevärn, Lotta Ohm, Ulla Olsson‐Strömberg, Kari Remes, Merja Suominen, Bengt Simonsson, Kimmo Porkka, Satu Mustjoki, Johan Richter

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

    Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients per Henrik Hjorth‐Hansen, Jesper Stentoft, Johan Richter, Perttu Koskenvesa, Martin Höglund, Arta Dreimane, Kimmo Porkka, Tobias Gedde‐Dahl, Bjørn Tore Gjertsen, Franz Gruber, Leif Stenke, Kristina Myhr Eriksson, Berit Markevärn, Anna Lübking, Hanne Vestergaard, Lene Udby, Ole Weis Bjerrum, Inger Persson, Satu Mustjoki, Ulla Olsson‐Strömberg

    Publicat 2016
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial

    Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial per Hjalmar Flygt, Stina Söderlund, Johan Richter, Susanne Saußele, Perttu Koskenvesa, Leif Stenke, Satu Mustjoki, Andreja Dimitrijevic, Jesper Stentoft, Waleed Majeed, Lydia Roy, Dominik Wolf‎, Arta Dreimane, Bjørn Tore Gjertsen, Tobias Gedde‐Dahl, Erik Ahlstrand, Berit Markevärn, Henrik Hjorth‐Hansen, Jeroen J.W.M. Janssen, Ulla Olsson‐Strömberg

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell cytotoxicity in chronic myeloid leukemia

    High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell cytotoxicity in chronic myeloid leukemia per Petra Nygren, Jonas Bouhlal, Emmi Jokinen, Sofia Forstén, Essi Laajala, Diogo Artur Alves Dias, Shady Adnan Awad, Aleksandr Ianevski, Jay Klievink, Hanna Lähteenmäki, Heikki Kuusanmäki, Mikko Myllymäki, Tiina Kasanen, Khalid Saeed, Dean A. Lee, iCAN Flagship, Henrik Hjorth‐Hansen, Tero Aittokallio, Olli Dufva, Satu Mustjoki

    Publicat 2025
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial

    Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled... per Peter Gimsing, Kristina Carlson, Ingemar Turesson, Peter Fayers, Anders Waage, Annette Juul Vangsted, Anne K. Mylin, Christian Gluud, Gunnar Juliusson, Henrik Gregersen, Henrik Hjorth‐Hansen, Ingerid Nesthus, Inger Marie S. Dahl, Jan Westin, Johan Lanng Nielsen, Lene Meldgaard Knudsen, Lucia Ahlberg, Martin Hjorth, Niels Abildgaard, Niels Frost Andersen, Olle Linder, Finn Wislöff

    Publicat 2010
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia

    Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia per Kimmo Porkka, Perttu Koskenvesa, Tuija Lundán, Johanna Rimpiläinen, Satu Mustjoki, Richard Smykla, Robert A. Wild, Roger Luo, Montserrat Arnán, Benoît Brethon, Lydia Eccersley, Henrik Hjorth‐Hansen, Martin Höglund, Hana Klamová, Håvar Knutsen, Suhag Parikh, Emmanuel Raffoux, Franz Gruber, F. Brito‐Babapulle, Hervé Dombret, Rafael F. Duarte, Erkki Elonen, Ron Paquette, C. Michel Zwaan, Francis Y. F. Lee

    Publicat 2008
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Cold agglutinin disease revisited: a multinational, observational study of 232 patients

    Cold agglutinin disease revisited: a multinational, observational study of 232 patients per Sigbjørn Berentsen, Wilma Barcellini, Shirley D’Sa, Ulla Randen, Tor Henrik Anderson Tvedt, Bruno Fattizzo, Einar Haukås, Megan Kell, Robert Brudevold, Anders Erik Astrup Dahm, Jakob Dalgaard, Hege Frøen, Randi Fykse Hallstensen, Pernille H. Jæger, Henrik Hjorth‐Hansen, Agnieszka Małecka, Markku Oksman, Jürgen Rolke, Mallika Sekhar, Jon Hjalmar Sørbø, Eirik Tjønnfjord, Galina Tsykunova, Geir E. Tjønnfjord

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

    Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia per Bengt Simonsson, Tobias Gedde‐Dahl, Berit Markevärn, Kari Remes, Jesper Stentoft, A. Almqvist, Mats Björeman, Max Flogegård, Perttu Koskenvesa, Anders Lindblom, Claes Malm, Satu Mustjoki, Kristina Myhr‐Eriksson, Lotta Ohm, Anu Räsänen, Marjatta Sinisalo, Anders Själander, Ulla Strömberg, Ole Weiss Bjerrum, Hans Ehrencrona, Franz Gruber, Veli Kairisto, Karin Olsson, Fredrik Sandin, Arnon Nagler, Johan Lanng Nielsen, Henrik Hjorth‐Hansen, Kimmo Porkka

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

    Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia per Mette Ilander, Ulla Olsson‐Strömberg, Heinrich Schlums, Joëlle Guilhot, Oscar Brück, Hanna Lähteenmäki, Tiina Kasanen, Perttu Koskenvesa, S Söderlund, Martin Höglund, Berit Markevärn, Anders Själander, Kourosh Lotfi, Arta Dreimane, Anna Lübking, Elena Holm, Mats Björeman, Sören Lehmann, Leif Stenke, Lotta Ohm, Tobias Gedde‐Dahl, Waleed Majeed, Hans Ehrencrona, Satu Koskela, Susanne Saußele, F-X Mahon, Kimmo Porkka, Henrik Hjorth‐Hansen, Yenan T. Bryceson, Johan Richter, Satu Mustjoki

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: